Raymond James Financial
ACAD icon

Raymond James Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Raymond James Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
100,094
+68,171
+214% +$1.5M ﹤0.01% 3320
2026
Q1 		$711K Buy
31,923
+11,274
+55% +$269K ﹤0.01% 4106
2025
Q4 		$552K Sell
20,649
-4,549
-18% -$109K ﹤0.01% 4202
2025
Q3 		$538K Sell
25,198
-4,481
-15% -$106K ﹤0.01% 4082
2025
Q2 		$640K Buy
29,679
+1,396
+5% +$25.9K ﹤0.01% 3851
2025
Q1 		$470K Sell
28,283
-7,878
-22% -$143K ﹤0.01% 3967
2024
Q4 		$664K Buy
+36,161
New +$584K ﹤0.01% 3724

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial's ACAD Position: Q2 2026 in Review

Raymond James Financial increased its Acadia Pharmaceuticals (ACAD) stake by 214% in Q2 2026, buying an estimated $1.5M and bringing the position to 100,094 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #3320.

Raymond James Financial first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Raymond James Financial held 100,094 shares of Acadia Pharmaceuticals worth $2.53M as of Q2 2026.
  • Raymond James Financial bought 68,171 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.5M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3320 holding.
  • Raymond James Financial first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.